Pfizer and Nektar reach agreement on Exubera

San Carlos-based Nektar Therapeutics (NKTR) has resolved a contract dispute with Pfizer Inc. (PFE) over its line of inhaled insulin products, the companies announced Tuesday.

Pfizer will pay Nektar $135 million to satisfy its obligations for contracts relating to Exubera, an inhaled insulin product, and agreed to transfer its remaining right to the product if Nektar finds another partner for its development and marketing, the compay said in a statement.

Pfizer announced it would discontinue Exhubera last month due to disappointing sales, taking a $2.8 billion charge in the third quarter as a result, according to the Associated Press.

The companies said they will continue to work together on PEGylated human growth hormone therapy for short stature and growth problems.

businessBusiness & Real Estate

If you find our journalism valuable and relevant, please consider joining our Examiner membership program.
Find out more at www.sfexaminer.com/join/

Just Posted

Free Muni for Youth program expansion halted by SFMTA budget crisis

Low- and moderate-income kids can still travel for free

Newsom orders multiple counties to shut down bars, indoor restaurants as COVID-19 cases rise

As confirmed cases of COVID-19 rise in California, Gov. Gavin Newsom on… Continue reading

SFPD chief broadly bans release of mugshots

San Francisco police will no longer release booking photos of people arrested… Continue reading

DPW employees call for more sanitary working conditions

Workers say they face limits on access to handwashing, restrooms

SFMTA approves temporary transit-only lanes to counter rising congestion

Agency expects car use, traffic to increase as residents return to work

Most Read